参考文献/References:
[1] 郭琰,刘栩岑,杨庆等. 炎症消散的缺失诱发As 斑块形成的作用机制及中药复方干预As 炎症新思路的探索[J]. 中国动脉硬化杂志,2015,23(11):1171-1176.
[2] Das UN. Arachidonic acid and other unsaturated fatty acids and some of their metabolites function as endogenous antimicrobial molecules:a review[J]. J Adv Res,2018,11:57-66.
[3] Chen F,Ghosh A,Lin J,et al. 5-lipoxygenase pathway and its downstream cysteinyl leukotrienes as potential therapeutic targets for Alzheimer’s disease[J]. Brain Behav Immun,2020,88:844-855.
[4] Haeggstr?m JZ. Leukotriene biosynthetic enzymes as therapeutic targets[J]. J Clin Invest, 2018,128(7):2680-2690.
[5] Shabaan MA,Kamal AM,Faggal SI,et al. Synthesis and biological evaluation of pyrazolone analogues as potential anti-inflammatory agents targeting cyclooxygenases and 5-lipoxygenase[J]. Arch Pharm (Weinheim),2020,353(4):e1900308.
[6] Spanbroek R,Hildner M,Steinhilber D,et al. 5-lipoxygenase expression in dendritic cells generated from CD34(+) hematopoietic progenitors and in lymphoid organs[J]. Blood,2000,96(12):3857-3865.
[7] Poirier SJ,Boudreau LH,Flamand N,et al. LPS induces ALOX5 promoter activation and 5-lipoxygenase expression in human monocytic cells[J]. Prostaglandins Leukot Essent Fatty Acids,2020,154:102078.
[8] Kumar RB,Purhonen P,Hebert H,et al. Arachidonic acid promotes the binding of 5-lipoxygenase on nanodiscs containing 5-lipoxygenase activating protein in the absence of calcium-ions[J]. PLoS One,2020,15(7):e0228607.
[9] Luo M,Jones SM,Phare SM,et al. Protein kinase A inhibits leukotriene synthesis by phosphorylation of 5-lipoxygenase on serine 523[J]. J Biol Chem,2004,279(40):41512-41520.
[10] Lai XF,Qin HD,Guo LL,et al. Hypercholesterolemia increases the production of leukotriene B4 in neutrophils by enhancing the nuclear localization of 5-lipoxygenase[J]. Cell Physiol Biochem,2014,34(5):1723-1732.
[11] Radmark O,Werz O,Steinhilber D,et al. 5-Lipoxygenase:regulation of expression and enzyme activity[J]. Trends Biochem Sci,2007,32(7):332-341.
[12] Dupouy C,Saban L,Dupré-Crochet S. The lipidosome:the site of LTB4 synthesis,a mediator of sterile inflammation[J]. Med Sci (Paris),2020,36(5):528-530.
[13] Pal K,Feng X,Steinke JW,et al. Leukotriene A4 Hydrolase Activation and Leukotriene B4 Production by Eosinophils in Severe Asthma[J]. Am J Respir Cell Mol Biol,2019, 60(4):413-419.
[14] Horii Y,Nakaya M,Ohara H,et al. Leukotriene B4 receptor 1 exacerbates inflammation following myocardial infarction[J]. FASEB J,2020,34(6) :8749-8763.
[15] Kwon SY,Kim JH. Role of Leukotriene B4 receptor-2 in mast cells in allergic airway inflammation[J]. Int J Mol Sci,2019,20(12):2897.
[16] Gilbert NC,Gerstmeier J,Schexnaydre EE,et al. Structural and mechanistic insights into 5-lipoxygenase inhibition by natural products[J]. Nat Chem Biol,2020,16(7):783-790.
[17] Febbraio M,Podrez EA,Smith JD,et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice[J]. J Clin Invest,2000,105(8):1049-1056.
[18] Mawhin MA,Tilly P,Zirka G,et al. Neutrophils recruited by leukotriene B4 induce features of plaque destabilization during endotoxaemia[J]. Cardiovasc Res,2018,114(12) :1656-1666.
[19] Huang L,Zhao A,Wong F,et al. Leukotriene B4 strongly increases monocyte chemoattractant protein-1 in human monocytes[J]. Arterioscler Thromb Vasc Biol,2004, 24(10) :1783-1788.
[20] Yun MR,Im DS,Lee SJ,et al. 4-Hydroxynonenal enhances CD36 expression on murine macrophages via p38 MAPK-mediated activation of 5-lipoxygenase[J]. Free Radic Biol Med,2009,46(5):692-698.
[21] Dias IHK,Griffiths HR. Current and future directions for targeting lipoxin A4 in Alzheimer’s disease[J]. J Alzheimers Dis,2021 ,81(1):87-90..
[22] Hersberger M. Potential role of the lipoxygenase derived lipid mediators in atherosclerosis:leukotrienes,lipoxins and resolvins[J]. Clin Chem Lab Med,2010, 48(8):1063-1073.
[23] Chen YC,Su MC,Chin CH,et al. Formyl peptide receptor 1 up-regulation and formyl peptide receptor 2/3 down-regulation of blood immune cells along with defective lipoxin A4/resolvin D1 production in obstructive sleep apnea patients [J]. PLoS One,2019, 14(5):e0216607.
[24] Wei F,Gong W,Wang J,et al. Role of the lipoxin A4 receptor in the development of neutrophil extracellular traps in Leishmania infantum infection[J]. Parasit Vectors,2019, 12(1):275.
[25] Fu T,Mohan M,Brennan EP,et al. Therapeutic potential of lipoxin A4 in chronic inflammation :focus on cardiometabolic disease[J]. ACS Pharmacol Transl Sci,2020,3(1):43-55.
[26] Ryan A,Godson C. Lipoxins:regulators of resolution[J]. Curr Opin Pharmacol,2010,10(2):166-172.
[27] Chen Y,Zheng Y,Xin L,et al. 15-epi-lipoxin A4 inhibits TNF-α-induced tissue factor expression via the PI3K/AKT/ NF-κB axis in human umbilical vein endothelial cells[J]. Biomed Pharmacother,2019,117 :109099.
[28] Hu XH,Situ HL,Chen JP,et al. Lipoxin A4 alleviates lung injury in sepsis rats through p38/MAPK signaling pathway[J]. J Biol Regul Homeost Agents,2020,34(3):807-814.
[29] Li Y,Wang N,Ma Z,et al. Lipoxin A4 protects against paraquat?induced acute lung injury by inhibiting the TLR4/MyD88?mediated activation of the NF?κB and PI3K/AKT pathways[J]. Int J Mol Med,2021,47(5):86.
[30] Pang Y,Gan L,Wang X,et al. Celecoxib aggravates atherogenesis and upregulates leukotrienes in ApoE-/- mice and lipopolysaccharide-stimulated RAW264.7 macrophages[J]. Atherosclerosis,2019,284 :50-58.
[31] Sinha S,Doble M,Manju SL. 5-Lipoxygenase as a drug target:a review on trends in inhibitors structural design,SAR and mechanism based approach[J]. Bioorg Med Chem,2019,27(17):3745-3759.
[32] Gur ZT,Caliskan B,Banoglu E. Drug discovery approaches targeting 5-lipoxygenase-activating protein (FLAP) for inhibition of cellular leukotriene biosynthesis[J]. Eur J Med Chem,2018,153:34-48.
[33] 张代娟,宫英芳,刘江月,等. 青心酮对ApoE(-/-)小鼠动脉粥样硬化斑块中巨噬细胞5-脂氧合酶的影响[J]. 中药新药与临床药理,2012,(3):243-246.
[34] Peng SY,Liu Y,Bao XH,et al. Inhibition of 5-lipoxygenase and cyclooxygenase-2 pathways by pain-relieving plaster in macrophages[J]. Pharm Biol,2011,49(7):716-726.
[35] Murashima T,Yamasaki M,Nishizawa Y,et al. Proliferation of estrogen-responsive mouse tumor cell line B-1F stimulated by Saiboku-to,but inhibited by Scutellaria baicalensis,a component of Saiboku-to[J]. Oncol Rep,2009,22(2):257-264.
[36] 李玉洁,杨庆,翁小刚,等. 活血、解毒——中药干预AS炎症反应的探索与尝试[J]. 中国药理学通报,2010,(5):577-580.
[37] Tobin DM,Ramakrishnan L. TB:the Yin and Yang of lipid mediators[J]. Curr Opin Pharmacol,2013,13(4):641-645.
相似文献/References:
[1]李乐亮,综述,李萍,等.炎症标志物与颈动脉粥样斑块的稳定性[J].心血管病学进展,2016,(3):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
LI Leliang,LI Ping.Stability of Inflammatory Markers and Carotid Artery Plaque[J].Advances in Cardiovascular Diseases,2016,(4):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
[2]耿春晖 关秀茹.MicroRNA作为动脉粥样硬化的诊断生物标志物的研究进展[J].心血管病学进展,2019,(7):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
GENG Chunhui,GUAN Xiuru.microRNA as a Diagnostic Biomarker for Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(4):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
[3]乐健 何胜虎.前蛋白转化酶枯草溶菌素9致动脉粥样硬化的机制研究进展[J].心血管病学进展,2019,(7):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
YUE Jian,HE Shenghu.Advances in the mechanism of PCSK9-induced atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(4):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
[4]武亚琳,梁斌,杨志明.NLRP3/IL-1β途径的促动脉粥样硬化作用及临床应用[J].心血管病学进展,2019,(6):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
WU Yalin,LIANG Bin,YANG Zhiming.The Role of NLRP3/IL-1in Atherosclerosis and Clinical Application[J].Advances in Cardiovascular Diseases,2019,(4):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
[5]李琦玉 ?张宁 陈婧 黄浙勇.动脉粥样硬化的抗血小板分子靶向治疗[J].心血管病学进展,2019,(5):701.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.010]
LI Qiyu,ZHANG Ning,CHEN Jing,et al.Anti-Platelet Molecular Targeted Therapy or Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(4):701.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.010]
[6]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(4):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[7]焦新峰 刘正霞 鲁翔.白介素-8在冠心病中的研究进展[J].心血管病学进展,2019,(8):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
JIAO Xinfeng,LIU Zhengxia,LU Xiang.Research Progress of Interleukin-8 in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(4):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
[8]徐侨 刘正霞 鲁翔.白介素22在动脉粥样硬化和2型糖尿病中的作用[J].心血管病学进展,2019,(9):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
XU Qiao,LIU Zhengxia,LU Xiang.IL-22 in Atherosclerosis and Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(4):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
[9]石文坚 花蕾 孟祥光 袁义强.环状RNA在冠状动脉粥样硬化性心脏病中的研究进展[J].心血管病学进展,2019,(9):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
SHI Wenjian,HUA Lei,MENG Xiangguang,et al.CircRNA in Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2019,(4):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
[10]代承忠 彭礼清 余建群 刘静 蒲华霞.双源CT血管成像评价经导管主动脉瓣置入术术前患者颈动脉斑块[J].心血管病学进展,2019,(8):1182.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.028]
DAI Chengzhong,PENG Liqing,YU Jianqun,et al.Evaluation of Carotid Arteries Plaques in Patients Referred for TAVI with Dual-source CT Angiography[J].Advances in Cardiovascular Diseases,2019,(4):1182.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.028]